Folotyn for Non-Hodgkin's Lymphoma Bellmore NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Ronald I Bash
(516) 627-1221
1201 Northern Blvd
Manhasset, NY
Louis Juden Reed
(718) 863-8465
1180 Morris Park Ave
Bronx, NY
VEENA JOHN, MD
(516) 734-8973
450 Lakeville Road
New Hyde Park, NY
Diana Nancy Contreras, MD
806-743-2757
1554 Northern Blvd
Manhasset, NY
Jonathan A Haas, MD
516-663-2501
259 1st St
Mineola, NY
Kenneth K Ng
(646) 227-3813
1000 N Village Ave
Rockville Centre, NY
Ivan K Rothman
(516) 536-1455
242 Merrick Rd
Rockville Centre, NY
Farida P Chaudhri MD
(718) 358-3057
146-01 45th Ave
Flushing, NY
JOPH STECKEL, MD
(516) 627-6188
535 Plandome Road
Manhasset, NY
Jonathan Eliahu Kolitz, MD
516-562-8970
300 Community Dr
Manhasset, NY
Data Provided by:
      

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Bellmore NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Bellmore NY